Biogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Biogen (BIIB) PT Raised to $355 at Leerink PartnersOctober 25, 2017 7:29 AM BMO Capital Upgrades Biogen (BIIB) to OutperformOctober 25, 2017 1:01 AM Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple SclerosisOctober 25, 2017 1:00 AM Biogen (BIIB) Weakness Is Buying Opportunity - Goldman SachsOctober 24, 2017 2:35 PM SPINRAZA Confusion Creates a Buying Opportunity in Biogen (BIIB) - StifelOctober 24, 2017 11:58 AM Dow jumps with upbeat 3M, Caterpillar earningsOctober 24, 2017 7:37 AM Biogen (BIIB) Tops Q3 EPS by 61cOctober 24, 2017 7:00 AM Biogen (BIIB) Announces Amended Agreement with Neurimmune Holding AG on Investigational Alzheimer's Disease Treatment Aducanumab October 24, 2017 6:31 AM Guggenheim Starts Biogen (BIIB) at BuyOctober 23, 2017 4:20 PM Biogen (BIIB) PT Raised to $430 at StifelOctober 23, 2017 11:53 AM Biogen (BIIB), Eisai Expand Pact to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 AducanumabOctober 23, 2017 7:16 AM UPDATE: Citi Downgrades Biogen (BIIB) to NeutralOctober 23, 2017 6:26 AM Piper Jaffray Assumes Biogen (BIIB) at OverweightOctober 23, 2017 4:43 AM